Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma

This study is testing a genetically modified virus (called Ad-TD-nsIL12) injected directly into the brainstem tumor in children with diffuse intrinsic pontine glioma (DIPG) — an aggressive brain tumor in the brainstem — that has come back or continued to grow after previous treatment. The goal is to use the virus to attack the cancer from within. **You may be eligible if...** - Your child is between 1 and 18 years old with confirmed DIPG that has progressed after prior treatment (confirmed by MRI and biopsy) - Your child is functional enough to participate (performance score of 50 or above) - Your child's blood counts (white cells, red cells, platelets) are within acceptable levels - The tumor location is accessible for a stereotactic (precise, computer-guided) biopsy and injection **You may NOT be eligible if...** - Your child has serious organ failure (heart, liver, kidneys, or bone marrow) - Your child has an immune deficiency, autoimmune disease, or active hepatitis - Your child has a tumor in multiple locations in the brain - Your child is pregnant or breastfeeding (for older adolescents) - Your child has Li-Fraumeni syndrome or certain inherited cancer predisposition syndromes Talk to your doctor to see if this trial is right for you.